- Investing Ideas
- French Pharmaceuticals & Biotech Undervalued over 20% based on DCF
French Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
5
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
5 companies
Ipsen
Market Cap: €13.0b
A biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally.
IPN
€157.90
7D
-6.5%
1Y
48.3%
Eurofins Scientific
Market Cap: €12.1b
Provides various analytical testing and laboratory services worldwide.
ERF
€69.50
7D
1.0%
1Y
14.6%
Virbac
Market Cap: €2.7b
Manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific.
VIRP
€326.50
7D
3.0%
1Y
-8.0%
Nanobiotix
Market Cap: €1.7b
Operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
NANO
€33.48
7D
-1.8%
1Y
628.6%
Eurobio Scientific Société anonyme
Market Cap: €212.4m
Engages in research, development, and marketing specialty diagnostic products in the areas of transplantation, infectious diseases, autoimmunity, oncology, and life sciences.
ALERS
€21.10
7D
-0.5%
1Y
-15.3%